Cereno Scientific

Cereno Scientific has launched the global Phase IIb study for CS1 (EPIMODE) in pulmonary arterial hypertension (PAH) with the activation of the first clinical site. We view this as a meaningful execution milestone, clearing the path to patient recruitment...

Cereno Scientific has reported a SEK60m capital raise through a directed share issue of c 11.8m new B-shares at SEK5.10/share. Notably, the financing was concluded at a 4.1% premium to the previous closing price (SEK4.9) and without any attached warrants...